Skip to content

Study · Non-randomized trial · n = 60 · 2017

7 results

GnRH Antagonist Cetrorelix Administration Before hCG for Protection of Ovarian Hyperstimulation Syndrome.

Hebisha SA, Aboelazm BA, Sallam HN

Journal of obstetrics and gynaecology of India29 Nov 2016Cited by 5 (Europe PMC)

PMID28706366 (opens in a new tab)PMCIDPMC5491409 (opens in a new tab)DOI10.1007/s13224-016-0952-5 (opens in a new tab)PepBankPUB-28706366
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In IVF/ICSI patients, pregnancy rates were significantly higher with a single cetrorelix dose than with two doses (80.7%, 42/52 versus 50%, 4/8, p = 0.047).

    In plain wordsIn IVF/ICSI patients, pregnancy rates were higher in those given one cetrorelix dose than in those given two doses.

    Peptide
    Cetrorelix
    Outcome
    IncreaseClinical pregnancy rate
    Study

    n = 60

    Comparator
    Two doses of cetrorelix 0.25 mg/day
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    single dose 0.25 mgAs given in this study (human).

    Measurements

    Pregnancy rate
    80.7%
    single dose
    Pregnancies
    42 patients
    single dose
    Pregnancy rate
    50%
    two doses
    Pregnancies
    4 patients
    two doses

    Source sentences

    Summary
    Clinical pregnancy rate was 76.6% (46/60), in patients received single dose of antagonist PR were significantly higher 80.7% (42/52) versus 50% (4/8) in patients received two doses p = 0.047.
    3 context sentences
    Summary · context
    Prospective study.
    Summary · context
    Sixty patients undergoing controlled hyperstimulation COH, for IVF/ICSI using long agonist and E2 level on the day of hCG, are above 5000 ng/dl,
    Summary · context
    52 patients received single dose of cetrorelix 0.25 mg on the day of hCG, and 8 patients received two doses of 0.25 mg/day cetrorelix started one day before the day of hCG.
  2. 02HumanNon-randomized trialEfficacy outcome

    In IVF/ICSI patients receiving cetrorelix, clinical pregnancy occurred in 46/60 patients (76.6%).

    In plain wordsIn IVF/ICSI patients receiving cetrorelix, clinical pregnancy occurred in 46/60 patients.

    Peptide
    Cetrorelix
    Outcome
    Not applicableOverall clinical pregnancy rate
    Study

    n = 60

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Pregnancy rate
    76.6%
    both schedules
    Pregnancies
    46 patients
    both schedules

    Source sentences

    Summary
    Clinical pregnancy rate was 76.6% (46/60), in patients received single dose of antagonist PR were significantly higher 80.7% (42/52) versus 50% (4/8) in patients received two doses p = 0.047.
    3 context sentences
    Summary · context
    Prospective study.
    Summary · context
    Sixty patients undergoing controlled hyperstimulation COH, for IVF/ICSI using long agonist and E2 level on the day of hCG, are above 5000 ng/dl,
    Summary · context
    52 patients received single dose of cetrorelix 0.25 mg on the day of hCG, and 8 patients received two doses of 0.25 mg/day cetrorelix started one day before the day of hCG.
  3. 03HumanNon-randomized trialEfficacy outcome

    In IVF/ICSI patients receiving cetrorelix, live birth occurred in 30/60 patients (50%).

    In plain wordsIn IVF/ICSI patients receiving cetrorelix, live birth occurred in 30/60 patients.

    Peptide
    Cetrorelix
    Outcome
    Not applicableLive birth rate
    Study

    n = 60

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Live birth rate
    50%
    both schedules
    Live births
    30 patients
    both schedules

    Source sentences

    Summary
    Live birth rate was 50% (30/60), abortion rate was 20% (12/60), and preterm delivery was 20% (12/60).
    3 context sentences
    Summary · context
    Prospective study.
    Summary · context
    Sixty patients undergoing controlled hyperstimulation COH, for IVF/ICSI using long agonist and E2 level on the day of hCG, are above 5000 ng/dl,
    Summary · context
    52 patients received single dose of cetrorelix 0.25 mg on the day of hCG, and 8 patients received two doses of 0.25 mg/day cetrorelix started one day before the day of hCG.
  4. 04HumanNon-randomized trialSafety outcome

    In IVF/ICSI patients receiving cetrorelix, abortion occurred in 12/60 patients (20%).

    In plain wordsIn IVF/ICSI patients receiving cetrorelix, abortion occurred in 12/60 patients.

    Peptide
    Cetrorelix
    Outcome
    Not applicableAbortion rate
    Study

    n = 60

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Abortion rate
    20%
    both schedules
    Abortions
    12 patients
    both schedules

    Source sentences

    Summary
    Live birth rate was 50% (30/60), abortion rate was 20% (12/60), and preterm delivery was 20% (12/60).
    3 context sentences
    Summary · context
    Prospective study.
    Summary · context
    Sixty patients undergoing controlled hyperstimulation COH, for IVF/ICSI using long agonist and E2 level on the day of hCG, are above 5000 ng/dl,
    Summary · context
    52 patients received single dose of cetrorelix 0.25 mg on the day of hCG, and 8 patients received two doses of 0.25 mg/day cetrorelix started one day before the day of hCG.
  5. 05HumanNon-randomized trialSafety outcome

    In IVF/ICSI patients receiving cetrorelix, preterm delivery occurred in 12/60 patients (20%).

    In plain wordsIn IVF/ICSI patients receiving cetrorelix, preterm delivery occurred in 12/60 patients.

    Peptide
    Cetrorelix
    Outcome
    Not applicablePreterm delivery
    Study

    n = 60

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Preterm delivery rate
    20%
    both schedules
    Preterm deliveries
    12 patients
    both schedules

    Source sentences

    Summary
    Live birth rate was 50% (30/60), abortion rate was 20% (12/60), and preterm delivery was 20% (12/60).
    3 context sentences
    Summary · context
    Prospective study.
    Summary · context
    Sixty patients undergoing controlled hyperstimulation COH, for IVF/ICSI using long agonist and E2 level on the day of hCG, are above 5000 ng/dl,
    Summary · context
    52 patients received single dose of cetrorelix 0.25 mg on the day of hCG, and 8 patients received two doses of 0.25 mg/day cetrorelix started one day before the day of hCG.
  6. 06HumanNon-randomized trialEfficacy outcome

    In IVF/ICSI patients receiving cetrorelix, moderate OHSS occurred in 6/60 patients (10%).

    In plain wordsIn IVF/ICSI patients receiving cetrorelix, moderate ovarian hyperstimulation occurred in 6/60 patients.

    Peptide
    Cetrorelix
    Outcome
    Not applicableModerate ovarian hyperstimulation syndrome
    Study

    n = 60

    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Moderate OHSS
    6 patients
    both schedules
    Moderate OHSS rate
    10%
    both schedules

    Source sentences

    Summary
    Six patients developed moderate ovarian hyperstimulation OHSS (6/60) 10% and no cases of severe OHSS.
    3 context sentences
    Summary · context
    Prospective study.
    Summary · context
    Sixty patients undergoing controlled hyperstimulation COH, for IVF/ICSI using long agonist and E2 level on the day of hCG, are above 5000 ng/dl,
    Summary · context
    52 patients received single dose of cetrorelix 0.25 mg on the day of hCG, and 8 patients received two doses of 0.25 mg/day cetrorelix started one day before the day of hCG.
  7. 07HumanNon-randomized trialEfficacy outcome

    In IVF/ICSI patients receiving cetrorelix, no severe OHSS cases occurred.

    In plain wordsIn IVF/ICSI patients receiving cetrorelix, no severe ovarian hyperstimulation cases occurred.

    Peptide
    Cetrorelix
    Outcome
    Not applicableSevere ovarian hyperstimulation syndrome
    Study

    n = 60

    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Six patients developed moderate ovarian hyperstimulation OHSS (6/60) 10% and no cases of severe OHSS.
    3 context sentences
    Summary · context
    Prospective study.
    Summary · context
    Sixty patients undergoing controlled hyperstimulation COH, for IVF/ICSI using long agonist and E2 level on the day of hCG, are above 5000 ng/dl,
    Summary · context
    52 patients received single dose of cetrorelix 0.25 mg on the day of hCG, and 8 patients received two doses of 0.25 mg/day cetrorelix started one day before the day of hCG.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.